TABLE 3.
Antibody response among Individuals with Pulmonary Tb and Controls
Subject | Titer
|
Predominant IgG subclass | % of maximal inhibition by:
|
||
---|---|---|---|---|---|
IgM | IgG | MAb 5c11 | MAb 9d8 | ||
Pulmonary TB patients | |||||
A | 1:150 | 1:109,350 | IgG2 | NIa | NI |
B | 1:150 | 1:36,150 | IgG1 | 70 | 79 |
C | 1:50 | 1:109,350 | IgG2 | 65 | 44 |
D | 1:150 | 1:36,150 | IgG1 | 46 | NI |
E | 1:450 | 1:109,350 | IgG2 | 77 | 81 |
F | 1:1,350 | 1:1,350 | IgG2 | 56 | NI |
G | 1:450 | 1:109,350 | IgG2 | 78 | NI |
H | 1:50 | 1:12,150 | IgG2 | 56 | NI |
I | 1:1,350 | 1:12,150 | NRb | 57 | NI |
J | 1:50 | 1:450 | NR | 40 | NI |
K | NR | 1:109,350 | IgG2 | NI | NI |
L | 1:4,050 | 1:12,150 | IgG2 | 58 | NI |
M | 1:150 | 1:4,050 | IgG2 | 52 | NI |
N | 1:50 | 1:450 | NR | NI | NI |
O | 1:150 | 1:12,150 | IgG2 | 57 | NI |
P | 1:150 | 1:36,150 | IgG2 | 63 | NI |
Q | 1:150 | 1:36,150 | IgG2 | 76 | NI |
R | 1:1,350 | 1:36,150 | IgG2 | NI | NI |
S | 1:150 | 1:12,150 | IgG2 | NI | NI |
T | 1:150 | 1:12,150 | IgG2 | NI | NI |
Controls | |||||
1 | 1:50 | 1:1,350 | IgG2 | 68 | NI |
2 | 1:1,350 | 1:4,050 | NR | 67 | NI |
3 | NR | 1:12,150 | IgG2 | 33 | NI |
4 | NR | 1:12,150 | IgG2 | 59 | NI |
5 | 1:50 | 1:1,350 | NR | 44 | NI |
6 | 1:1,350 | 1:450 | IgG2 | 51 | NI |
7 | 1:50 | 1:4,050 | NR | 58 | NI |
8 | 1:50 | 1:1,350 | NR | 59 | NI |
9 | 1:50 | NR | NR | NI | NI |
10 | 1:50 | 1:1,350 | IgG2 | 67 | NI |
11 | 1:150 | 1:4,050 | NR | NI | NI |
12 | 1:450 | 1:36,150 | IgG2 | 75 | NI |
13 | NR | 1:1,350 | IgG2 | NI | NI |
14 | NR | 1:450 | IgG4 | 77 | NI |
15 | 1:50 | 1:4,050 | IgG2 | NI | NI |
16 | 1:150 | 1:450 | IgG2 | 71 | NI |
17 | 1:50 | 1:4,050 | IgG2 | 52 | NI |
NI, no inhibition.
NR, nonreactive.